Medicus Pharma Ltd. (MDCX) · Nov 19, 2026 · Delisting

Medicus Pharma Nasdaq compliance returns, but December test remains

Conditional compliance — $2.5M equity requirement; next test is the December 31, 2026 report

Medicus Pharma’s Nasdaq compliance is restored after financings and debt exchange, but the listing remains conditional on its December 31 equity test.

Medicus is a cash-burning, precision-oncology-led biotech trying to advance CD228V while keeping its financing structure intact; its September 30 filing showed negative shareholders’ equity and $31.9 million of operating cash use year to date. The immediate listing threat is paused, not eliminated. Nasdaq lifted the market-value deficiency after the company qualified under the alternative $2.5 million shareholders’ equity standard.

ItemNovember 2026Requirement / reference
Equity financing (Press release)$4.25M
Debt exchanged for preferred shares (Press release)$10.5M
Nasdaq shareholders’ equity threshold (Item 8.01)$2.5M

The fix was financial engineering rather than operating progress. The company raised approximately $4.25 million in equity and exchanged $10.5 million of debt for preferred shares, actions that were already disclosed in the November 16 transaction filing; this notice mainly confirms Nasdaq’s acceptance of that structure.

The key weakness is that compliance is conditional and the balance-sheet cushion is thin. Medicus must demonstrate continued compliance in its report for the period ending December 31, 2026, or it may again face delisting proceedings. 〔0〕

Bottom line: This removes an immediate Nasdaq overhang and preserves the listing for now, but it does not materially improve the underlying biotech execution story. The real test is whether the financing-driven equity improvement survives through year-end.

What to watch next

FY 2026 report for period ending December 31, 2026

Original filing on SEC EDGAR

More Medicus Pharma Ltd. news

Medicus Pharma Nasdaq compliance returns, but December test remains | MDCX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.